AlphaCore Capital’s AstraZeneca AZN Stock Holding History

AlphaCore Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$815K	Buy	4,299 +726	+20%	+$137K	0.02%	512
2026 Q1	$705K	Sell	3,573 -3,553	-50%	-$685K	0.02%	461
2025 Q4	$1.31M	Buy	7,126 +11	+0.2%	+$1.93K	0.03%	349
2025 Q3	$1.09M	Buy	7,115 +3,103	+77%	+$470K	0.04%	283
2025 Q2	$561K	Buy	4,012 +2,168	+118%	+$304K	0.02%	356
2025 Q1	$271K	Buy	+1,844	New	+$267K	0.02%	379
2020 Q2	–	Sell	-154	Closed	-$14K	–	86
2020 Q1	$14K	Buy	+154	New	+$14.5K	0.01%	181

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AlphaCore Capital's AZN Position: Q2 2026 in Review

AlphaCore Capital increased its AstraZeneca (AZN) stake by 20% in Q2 2026, buying an estimated $137K and bringing the position to 4,299 shares worth $815K. The position accounts for 0.02% of the portfolio, ranked #512.

AlphaCore Capital first reported a position in AZN in Q1 2020 and has held it in 7 quarters since. The position peaked at $1.31M in Q4 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

AlphaCore Capital held 4,299 shares of AstraZeneca worth $815K as of Q2 2026.
AlphaCore Capital bought 726 AstraZeneca shares in Q2 2026, an estimated $137K.
AstraZeneca made up 0.02% of AlphaCore Capital's portfolio in Q2 2026, its #512 holding.
AlphaCore Capital first reported a position in AstraZeneca in Q1 2020 and has held it in 7 quarters since.
AlphaCore Capital's AstraZeneca position peaked at $1.31M in Q4 2025.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.